PTC Therapeutics, Inc.
PTCT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $807 | $938 | $699 | $539 |
| % Growth | -14% | 34.2% | 29.7% | – |
| Cost of Goods Sold | $57 | $65 | $45 | $32 |
| Gross Profit | $749 | $872 | $654 | $506 |
| % Margin | 92.9% | 93% | 93.6% | 94% |
| R&D Expenses | $534 | $667 | $651 | $541 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $301 | $333 | $326 | $286 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $217 | $313 | $124 | $54 |
| Operating Expenses | $1,052 | $1,312 | $1,102 | $881 |
| Operating Income | -$303 | -$440 | -$447 | -$374 |
| % Margin | -37.5% | -46.9% | -64% | -69.5% |
| Other Income/Exp. Net | -$61 | -$257 | -$140 | -$144 |
| Pre-Tax Income | -$363 | -$696 | -$587 | -$518 |
| Tax Expense | $0 | -$70 | -$28 | $6 |
| Net Income | -$363 | -$627 | -$559 | -$524 |
| % Margin | -45% | -66.8% | -80% | -97.3% |
| EPS | -4.73 | -8.37 | -7.79 | -7.43 |
| % Growth | 43.5% | -7.4% | -4.8% | – |
| EPS Diluted | -4.73 | -8.37 | -7.79 | -7.43 |
| Weighted Avg Shares Out | 77 | 75 | 72 | 70 |
| Weighted Avg Shares Out Dil | 77 | 75 | 72 | 70 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $167 | $129 | $91 | $86 |
| Depreciation & Amortization | $76 | $237 | $129 | $64 |
| EBITDA | -$120 | -$330 | -$368 | -$368 |
| % Margin | -14.9% | -35.2% | -52.6% | -68.4% |